The table below lists all targeted cancer therapies with regulatory approval as of July 2017, grouped by their respective mechanisms of action.
| Main Group | Mechanism of Action | Substances (Targets) |
|---|---|---|
| Anti-Hormone Therapies | Estrogen Receptor Modulators | Diethylstilbestrol, Fulvestrant, Tamoxifen, Toremifen |
| Aromatase Inhibitors | Anastrozole, Exemestane, Letrozole | |
| Androgen Receptor Inhibitors | Bicalutamide, Enzalutamide, Flutamide | |
| GnRH Receptor Modulators | Abarelix, Degarelix, Leuprorelin, Triptorelin | |
| (Growth-) Receptor Inhibitors | Intracellular Tyrosine Kinase Inhibitors | Afatinib (EGFR), Brigatinib (ALK, EGFR), Erlotinib (EGFR, HER1R), Gefitinib (EGFR), Lapatinib (EGFR, HER2), Lenvatinib (VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET), Neratinib (EGFR, HER2), Osimertinib (EGFR T790M), Sunitinib (PDGF, VEGF, KIT, FLT, RET) |
| Extracellular Receptor Inhibitors | Bevacizumab (VEGF), Cetuximab (EGFR), Dinutuximab (GD2), Necitumumab (EGFR), Olaratumab (PDGFRα), Panitumumab (EGFR), Pertuzumab (HER2), Trastuzumab (HER2) | |
| Protein Inhibitors | ALK Inhibitors | Alectinib, Ceritinib, Crizotinib (ALK, MET, ROS1) |
| B-Raf Inhibitors | Dabrafenib, Encorafenib, Vemurafenib | |
| BCR-ABL Inhibitors | Dasatinib (BCR-ABL, SRC), Imatinib (BCR-ABL), Nilotinib (BCR-ABL) | |
| MEK Inhibitors | Binimetinib, Cobimetinib, Trametinib | |
| mTOR Inhibitors | Everolimus, Temsirolimus | |
| Immunotherapy | Immune-Checkpoint Inhibitors | Atezolizumab (PD-L1), Avelumab (PD-L1), Durvalumab (PD-L1), Ipilimumab (CTLA-4), Nivolumab (PD-1), Pembrolizumab (PD-1) |